Phase I trial of CD19 CAR-T cells with a PD1/CD28 switch receptor for relapsed or refractory B-cell lymphoma

CD19 CAR-T therapy achieves high remission rates in relapsed/refractory (R/R) B-cell lymphoma but is often limited by PD1/PD-L1–mediated immune suppression. A PD1/CD28 switch receptor may convert inhibitory PD1 signals into CD28 costimulation, enhancing efficacy. In this single-center, phase I trial, adults with R/R B-cell lymphoma received autologous CD19 CAR-T cells incorporating a PD1/CD28 switch receptor. Treatment followed a 3 + 3 dose-escalation design with subsequent expansion cohorts. Primary endpoints were safety and feasibility; secondary endpoints included efficacy, survival, CAR-T kinetics, and biomarker correlations. Thirty-two patients received CAR-T cells. In dose escalation, 6/9 responded (overall response rate [ORR] 66.7%; complete response [CR] 44.4%). Based on favorable responses at the highest dose (3 × 10^6/kg), 23 additional patients were treated, yielding ORR 87.0% and CR 69.6%. At median follow-up of 34 months, median duration of response (DOR) and overall survival (OS) were not reached; 12- and 36-month DOR rates were 58.6% and 53.3%. Median progression-free survival (PFS) was 12 months, with 3-year PFS 43.3%; 1- and 3-year OS were 82% and 64%. Cytokine release syndrome occurred in 62.5% (all grade 1–2) and neurotoxicity in 6.3% (grade 2–3). No significant association was detected between baseline PD-L1 expression and response. CD19&PD1/CD28 CAR-T therapy achieved high response rates, durable remissions, and manageable toxicity in R/R B-cell lymphoma. Responses occurred across baseline PD-L1 strata, but the single-arm design precludes attribution of efficacy to the switch receptor. Trial registration ClinicalTrials.gov Identifier NCT03932955.

Authors

Institutions

Publication Details

Journal
Experimental Hematology and Oncology
Published
2026-11-21
DOI
https://doi.org/10.1186/s40164-026-00866-1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phase I trial of CD19 CAR-T cells with a PD1/CD28 switch receptor for relapsed or refractory B-cell lymphoma

Jun Zhu, Yingchi Zhao, Shance Li, Chaoting Zhang et al.
Experimental Hematology and Oncology
CAR-T cell therapy research
article

Phase I trial of CD19 CAR-T cells with a PD1/CD28 switch receptor for relapsed or refractory B-cell lymphoma

Jun Zhu, Yingchi Zhao, Shance Li, Chaoting Zhang, Li Qu, Yongjing Tang, Tingting Du, Ningjing Lin, Luyan Shen, Bo Ma, Yuqin Song, Yan Xie, Zheming Lu, Wen Zheng
article en

Abstract

CD19 CAR-T therapy achieves high remission rates in relapsed/refractory (R/R) B-cell lymphoma but is often limited by PD1/PD-L1–mediated immune suppression. A PD1/CD28 switch receptor may convert inhibitory PD1 signals into CD28 costimulation, enhancing efficacy. In this single-center, phase I trial, adults with R/R B-cell lymphoma received autologous CD19 CAR-T cells incorporating a PD1/CD28 switch receptor. Treatment followed a 3 + 3 dose-escalation design with subsequent expansion cohorts. Primary endpoints were safety and feasibility; secondary endpoints included efficacy, survival, CAR-T kinetics, and biomarker correlations. Thirty-two patients received CAR-T cells. In dose escalation, 6/9 responded (overall response rate [ORR] 66.7%; complete response [CR] 44.4%). Based on favorable responses at the highest dose (3 × 10^6/kg), 23 additional patients were treated, yielding ORR 87.0% and CR 69.6%. At median follow-up of 34 months, median duration of response (DOR) and overall survival (OS) were not reached; 12- and 36-month DOR rates were 58.6% and 53.3%. Median progression-free survival (PFS) was 12 months, with 3-year PFS 43.3%; 1- and 3-year OS were 82% and 64%. Cytokine release syndrome occurred in 62.5% (all grade 1–2) and neurotoxicity in 6.3% (grade 2–3). No significant association was detected between baseline PD-L1 expression and response. CD19&PD1/CD28 CAR-T therapy achieved high response rates, durable remissions, and manageable toxicity in R/R B-cell lymphoma. Responses occurred across baseline PD-L1 strata, but the single-arm design precludes attribution of efficacy to the switch receptor. Trial registration ClinicalTrials.gov Identifier NCT03932955.

Experimental Hematology and OncologyVol. 15(1)
Peking University Cancer Hospital (CN), Ministry of Education (ET)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon